← Russell 3000 cross-section

XFOR X4 Pharmaceuticals, Inc

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$429m
Revenue TTM
$16m
Net income TTM
$-90m
Free cash flow
Composite score
Sector rank
#2472

Valuation

P / E
EV / EBITDA
EV / sales
19.5
FCF yield
Earnings yield vs 10-yr
-25.74pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-568.8%
EBITDA margin
-544.2%
ROE
-58.0%
ROIC
-248.6%
Revenue growth

Insider activity, last 90 days

Net open-market
$-0.36m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

CN disorders are rare blood conditions similarly characterized by increased risks of infections and cancer due to abnormally low levels of neutrophils in the body. Net product revenue was $ 1.7 million and $ 2.7 million for the three and six months ended June 30, 2025, respectively. 15 X4 PHARMACEUTICALS, INC. As of June 30, 2026, deferred revenue related to the Norgine Agreement was $ 1.4 million, of which $ 0.8 million was current. 5. …X4 Pharmaceuticals, Inc, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →